PYPD PolyPid Ltd. Stock Quote

PYPD [NASD]

Index	-	P/E	-	EPS (ttm)	-1.78	Insider Own	13.72%	Shs Outstand	18.75M	Perf Week	8.11%
Market Cap	146.72M	Forward P/E	-	EPS next Y	-2.36	Insider Trans	0.00%	Shs Float	16.18M	Perf Month	-0.37%
Income	-33.20M	PEG	-	EPS next Q	-0.62	Inst Own	19.40%	Short Float	0.13%	Perf Quarter	-12.28%
Sales	-	P/S	-	EPS this Y	-420.40%	Inst Trans	-3.05%	Short Ratio	0.73	Perf Half Y	-19.19%
Book/sh	3.03	P/B	2.64	EPS next Y	-7.10%	ROA	-46.00%	Target Price	-	Perf Year	-36.05%
Cash/sh	2.61	P/C	3.07	EPS next 5Y	-	ROE	-48.20%	52W Range	6.95 - 16.50	Perf YTD	-19.19%
Dividend	-	P/FCF	-	EPS past 5Y	-20.50%	ROI	-	52W High	-52.24%	Beta	-
Dividend %	-	Quick Ratio	11.40	Sales past 5Y	-	Gross Margin	-	52W Low	13.38%	ATR	0.41
Employees	57	Current Ratio	11.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	46.25	Volatility	5.43% 5.04%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	50.10%	Profit Margin	-	Rel Volume	0.95	Prev Close	8.00
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Aug 11 BMO	Payout	-	Avg Volume	28.92K	Price	7.88
Recom	1.80	SMA20	-4.47%	SMA50	-2.24%	SMA200	-17.45%	Volume	26,447	Change	-1.50%

Sep-14-21

Initiated

JMP Securities

Mkt Outperform

$14

Jul-30-21

Initiated

Cantor Fitzgerald

Overweight

$24

Nov-24-20

Upgrade

Raymond James

Outperform → Strong Buy

Aug-10-20

Initiated

Alliance Global Partners

Buy

$27

Jul-21-20

Initiated

Raymond James

Outperform

$23

Jul-21-20

Initiated

BMO Capital Markets

Outperform

$30

Jul-21-20

Initiated

Barclays

Overweight

$22

Sep-20-21 07:00AM	PolyPid to Present at Upcoming Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
Sep-13-21 11:00AM	PolyPid Shares Preclinical Data Of OncoPLEX Program For Brain Tumor Benzinga -7.81%
07:30AM	PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer GlobeNewswire
Aug-17-21 08:00AM	PolyPid to Present at First World Association Against Infection in Orthopaedics and Trauma Congress GlobeNewswire
Aug-11-21 07:00AM	PolyPid Ltd. Reports Second Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
Aug-09-21 08:00AM	PolyPid to Present at the Investor Summit Virtual Conference on August 18, 2021 GlobeNewswire +12.86%
Jul-28-21 07:00AM	PolyPid to Report Second Quarter 2021 Financial Results and Operational Highlights on August 11, 2021 GlobeNewswire
Jul-12-21 08:00AM	PolyPid Strengthens Executive Team, Appointing Dr. Anthony Senagore as Senior Medical Director GlobeNewswire
Jun-28-21 09:30AM	What Kind Of Shareholders Hold The Majority In PolyPid Ltd.'s (NASDAQ:PYPD) Shares? Simply Wall St.
Jun-23-21 06:30AM	PolyPid Presents today at The Raymond James Human Health Innovation Conference GlobeNewswire
Jun-22-21 09:58PM	Is PolyPid Ltd. (PYPD) A Good Stock To Buy? Insider Monkey
Jun-02-21 09:10AM	PolyPid to Present at Upcoming Healthcare Investor Conferences GlobeNewswire
May-19-21 12:51PM	PolyPid's Single Pivotal Study Sufficient To Support Potential Approval Of D-PLEX100 For Infections After Colorectal Surgery Benzinga
08:00AM	PolyPid Announces Positive FDA Type B Meeting Feedback for D-PLEX Development Program GlobeNewswire
May-12-21 07:00AM	PolyPid Ltd. Reports First Quarter 2021 Financial Results and Provides Corporate Update GlobeNewswire
06:45AM	Polypid Ltd to Host Earnings Call ACCESSWIRE
Apr-29-21 07:00AM	PolyPid to Report First Quarter 2021 Financial Results and Operational Highlights on May 12, 2021 GlobeNewswire
Mar-29-21 08:33AM	Here's Why We're Not Too Worried About PolyPid's (NASDAQ:PYPD) Cash Burn Situation Simply Wall St.
Feb-23-21 07:30AM	PolyPid to Participate in Upcoming Investor Conferences GlobeNewswire -10.87%
Feb-16-21 07:31AM	PolyPid Announces 100th Patient Enrolled in SHIELD I Phase 3 Clinical Trial of D-PLEX for the Prevention of Post-Abdominal Surgery Incisional Infections GlobeNewswire
Feb-10-21 07:34AM	The Daily Biotech Pulse: Lilly COVID-19 Antibody Cocktail Approved for Emergency Use, Gamida, Genfit Jump On Data, 2 IPOs Benzinga +7.76%
07:00AM	PolyPid Ltd. Provides Corporate Update and Reports Fourth Quarter and Full-Year 2020 Financial Results GlobeNewswire
06:30AM	Polypid Ltd to Host Earnings Call ACCESSWIRE
Jan-27-21 07:30AM	PolyPid to Report Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights on February 10, 2021 GlobeNewswire
Dec-22-20 07:00AM	PolyPid Announces Positive Preclinical Data from OncoPLEX Intra-Tumoral Cancer Therapy Program GlobeNewswire
Dec-16-20 07:00AM	PolyPid Initiates SHIELD II: Second Phase 3 Clinical Trial of D-PLEX for the Prevention of Post-Abdominal Surgery Incisional Infections GlobeNewswire -5.13%
Dec-03-20 08:00AM	PolyPid to Host Key Opinion Leader Call Discussing D-PLEX and the Prevention of Surgical Site Infections GlobeNewswire -5.32%
Nov-24-20 08:17AM	PolyPid Granted Breakthrough Therapy Designation from FDA for D-PLEX for the Prevention of Surgical Site Infections in Colorectal Surgery GlobeNewswire +15.54%
Nov-11-20 06:30AM	PolyPid Ltd. Provides Corporate Update and Reports Third Quarter 2020 Financial Results GlobeNewswire
Nov-04-20 08:45AM	PolyPid to Participate in Three Upcoming Investor Conferences GlobeNewswire
Oct-28-20 07:00AM	PolyPid to Report Third Quarter 2020 Financial Results and Operational Highlights on November 11, 2020 GlobeNewswire -7.09%
Oct-14-20 10:29AM	Raymond James Says These 3 Stocks Could Surge Over 100% From Current Levels TipRanks
Sep-28-20 01:28PM	We Think PolyPid (NASDAQ:PYPD) Can Afford To Drive Business Growth Simply Wall St. -12.87%
Aug-19-20 07:00AM	PolyPid Ltd. Provides Corporate Update and Reports Second Quarter 2020 Financial Results GlobeNewswire
Aug-05-20 04:01PM	PolyPid to Report Second Quarter 2020 Financial Results and Operational Highlights on August 19, 2020 GlobeNewswire
Aug-03-20 07:00AM	PolyPid Granted Fast Track Designation from FDA for D-PLEX for Prevention of Surgical Site Infections in Abdominal Surgery GlobeNewswire
Jul-27-20 07:00AM	PolyPid to Present Phase 2 Results of D-PLEX for the Prevention of Surgical Site Infections in Abdominal Surgery at the American Society of Colon and Rectal Surgeons 2020 Annual Scientific Conference Recorded Sessions GlobeNewswire
Jul-01-20 09:00AM	PolyPid Initiates First Phase 3 Clinical Trial of D-PLEX100 for the Prevention of Post-Abdominal Surgery Incisional Infections PR Newswire -8.04%
Jun-30-20 04:01PM	PolyPid Ltd. Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire -5.06%
Jun-26-20 02:04AM	PolyPid Ltd. Announces Pricing of Initial Public Offering PR Newswire

PolyPid Ltd., a late-stage biopharma company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product includes D-PLEX100, which is in Phase 3 clinical trial for the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience